Literature DB >> 23956247

Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis.

Rachel Knevel1, Kerstin Klein2, Klaartje Somers3, Caroline Ospelt2, Jeanine J Houwing-Duistermaat4, Jessica A B van Nies1, Diederik P C de Rooy1, Laura de Bock3, Fina A S Kurreeman5, Joris Schonkeren1, Gerrie Stoeken-Rijsbergen1, Quinta Helmer4, Michael P M van der Linden1, Marlena Kern6, Nataly Manjarrez-Orduno6, Luis Rodriguez-Rodriquez6, Piet Stinissen3, Tom W J Huizinga1, Rene E M Toes1, Steffen Gay2, Peter K Gregersen6, Veerle Somers3, Annette H M van der Helm-van Mil1.   

Abstract

BACKGROUND: Joint destruction is a hallmark of autoantibody-positive rheumatoid arthritis (RA), though the severity is highly variable between patients. The processes underlying these interindividual differences are incompletely understood.
METHODS: We performed a genome-wide association study on the radiological progression rate in 384 autoantibody-positive patients with RA. In stage-II 1557 X-rays of 301 Dutch autoantibody-positive patients with RA were studied and in stage-III 861 X-rays of 742 North American autoantibody-positive patients with RA. Sperm-Associated Antigen 16 (SPAG16) expression in RA synovium and fibroblast-like synoviocytes (FLS) was examined using Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) and immunohistochemistry. FLS secrete metalloproteinases that degrade cartilage and bone. SPAG16 genotypes were related to matrix metalloproteinase (MMP)-3 and MMP-1 expression by FLS in vitro and MMP-3 production ex vivo.
RESULTS: A cluster of single nucleotide polymorphisms (SNPs) at 2q34, located at SPAG16, associated with the radiological progression rate; rs7607479 reached genome-wide significance. A protective role of rs7607479 was replicated in European and North American patients with RA. Per minor allele, patients had a 0.78-fold (95% CI 0.67 to 0.91) progression rate over 7 years. mRNA and protein expression of SPAG16 in RA synovium and FLS was verified. FLS carrying the minor allele secreted less MMP-3 (p=1.60×10(-2)). Furthermore, patients with RA carrying the minor allele had lower serum levels of MMP-3 (p=4.28×10(-2)). In a multivariate analysis on rs7607479 and MMP-3, only MMP-3 associated with progression (p=2.77×10(-4)), suggesting that the association between SPAG16-rs7607479 and joint damage is mediated via an effect on MMP-3 secretion.
CONCLUSIONS: Genetic and functional analyses indicate that SPAG16 influences MMP-3 regulation and protects against joint destruction in autoantibody-positive RA. These findings could enhance risk stratification in autoantibody-positive RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Gene Polymorphism; Outcomes Research; Rheumatoid Arthritis

Mesh:

Substances:

Year:  2013        PMID: 23956247     DOI: 10.1136/annrheumdis-2013-204050

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?

Authors:  Ian C Scott; Frühling Rijsdijk; Jemma Walker; Jelmar Quist; Sarah L Spain; Rachael Tan; Sophia Steer; Yukinori Okada; Soumya Raychaudhuri; Andrew P Cope; Cathryn M Lewis
Journal:  J Rheumatol       Date:  2015-05-15       Impact factor: 4.666

Review 2.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 3.  The Tumor-Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine.

Authors:  Sungyong You; Jung Hee Koh; Lin Leng; Wan-Uk Kim; Richard Bucala
Journal:  Arthritis Rheumatol       Date:  2018-03-31       Impact factor: 10.995

Review 4.  Mammalian axoneme central pair complex proteins: Broader roles revealed by gene knockout phenotypes.

Authors:  Maria E Teves; David R Nagarkatti-Gude; Zhibing Zhang; Jerome F Strauss
Journal:  Cytoskeleton (Hoboken)       Date:  2016-01

Review 5.  One genome, many cell states: epigenetic control of innate immunity.

Authors:  Isabella Fraschilla; Hajera Amatullah; Kate L Jeffrey
Journal:  Curr Opin Immunol       Date:  2022-04-08       Impact factor: 7.268

6.  The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study.

Authors:  Koichi Murata; Motomu Hashimoto; Wataru Yamamoto; Yonsu Son; Hideki Amuro; Koji Nagai; Tohru Takeuchi; Masaki Katayama; Yuichi Maeda; Kosuke Ebina; Ryota Hara; Sadao Jinno; Akira Onishi; Kosaku Murakami; Masao Tanaka; Hiromu Ito; Tsuneyo Mimori; Shuichi Matsuda
Journal:  Rheumatol Int       Date:  2019-10-16       Impact factor: 2.631

Review 7.  Potential clinical biomarkers in rheumatoid arthritis with an omic approach.

Authors:  Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda
Journal:  Auto Immun Highlights       Date:  2021-05-31

8.  SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.

Authors:  Tomoyuki Mukai; Richard Gallant; Shu Ishida; Teruhito Yoshitaka; Mizuho Kittaka; Keiichiro Nishida; David A Fox; Yoshitaka Morita; Yasuyoshi Ueki
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

9.  A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis.

Authors:  Hanna W van Steenbergen; Luis Rodríguez-Rodríguez; Ewa Berglin; Alexandra Zhernakova; Rachel Knevel; Jose Ivorra-Cortés; Tom W J Huizinga; Benjamin Fernández-Gutiérrez; Peter K Gregersen; Solbritt Rantapää-Dahlqvist; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2015-01-08       Impact factor: 5.156

10.  A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis.

Authors:  Rachel Knevel; Diederik P C de Rooy; Tore Saxne; Elisabet Lindqvist; Martha K Leijsma; Nina A Daha; Bobby P C Koeleman; Roula Tsonaka; Jeanine J Houwing-Duistermaat; Joris J M Schonkeren; Rene E M Toes; Tom W J Huizinga; Elisabeth Brouwer; Anthony G Wilson; Annette H M van der Helm-van Mil
Journal:  Arthritis Res Ther       Date:  2014-05-07       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.